Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Petlife Pharmaceuticals's Enterprise Value for the quarter that ended in Feb. 2018 was $1.68 Mil.
Petlife Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Feb. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petlife Pharmaceuticals EV-to-EBIT Related Terms
Petlife Pharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Petlife Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petlife Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petlife Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Petlife Pharmaceuticals's EV-to-EBIT falls into.
Petlife Pharmaceuticals's current Enterprise Value is $0.02 Mil.
Petlife Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Feb. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petlife Pharmaceuticals (PTLF) has a EV-to-EBIT of -0.01 as of Aug. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Petlife Pharmaceuticals and its competitors.
Is Petlife Pharmaceuticals' EV-to-EBIT too high?
Petlife Pharmaceuticals' current EV-to-EBIT is -0.01.
How does Petlife Pharmaceuticals' EV-to-EBIT compare to PCYN and YBAO?
Petlife Pharmaceuticals' EV-to-EBIT of -0.01 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBIT is 15.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.99, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Petlife Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petlife Pharmaceuticals's current EV-to-EBIT is -0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petlife Pharmaceuticals stock overvalued right now?
Petlife Pharmaceuticals (PTLF) has a current EV-to-EBIT of -0.01. The current EV-to-EBIT is -0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Petlife Pharmaceuticals (PTLF), the current EV-to-EBIT is -0.01 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petlife Pharmaceuticals Inc specializes in the research, development, sales, and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis. It develops potentiated veterinary cancer medications and nutraceuticals, under its tradename Vitalzul based on Escozine formula. The Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins, and minerals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTLF has been successfully added to your 
